NASDAQ: OCSOculis Holding Ag Stock
$11.98+0.01 (+0.08%)
Updated Apr 24, 2024
OCS Price
$11.98
Fair Value Price
$0.48
Market Cap
$439.06M
52 Week Low
$9.05
52 Week High
$14.50
P/E
-3.55x
P/B
4.12x
P/S
390.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.00M
Earnings
-$105.72M
Gross Margin
100%
Operating Margin
-9,895.81%
Profit Margin
-10,056.9%
Debt to Equity
0.22
Operating Cash Flow
-$64M
Beta
0.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OCS Overview
European Biotech Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets opportunities in the life sciences industry in Europe. European Biotech Acquisition was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCS ($11.98) is overvalued by 2,370.42% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OCS ($11.98) is not significantly undervalued (2,370.42%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OCS due diligence checks available for Premium users.
Be the first to know about important OCS news, forecast changes, insider trades & much more!
OCS News
Valuation
OCS fair value
Fair Value of OCS stock based on Discounted Cash Flow (DCF)
Price
$11.98
Fair Value
$0.48
Overvalued by
2,370.42%
OCS ($11.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OCS ($11.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.55x
Industry
15.69x
Market
41.27x
OCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.12x
Industry
5.86x
OCS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCS's financial health
Profit margin
Revenue
$220.2k
Net Income
-$14.9M
Profit Margin
-6,756.2%
OCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OCS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$136.1M
Liabilities
$24.6M
Debt to equity
0.22
OCS's short-term assets ($114.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCS's short-term assets ($114.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.5M
Investing
$25.8M
Financing
$554.8k
OCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCS vs Biotech Stocks
Oculis Holding Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.